finance.yahoo.comAUG 242 min read$NEO

NeoGenomics, Inc. (NEO) Hits Fresh High: Is There Still Room to Run?

NeoGenomics (NEO) stock rose 22.3% in the past month, hitting a 52-week high of $17.08. The company beat earnings estimates in the last four quarters. For the current fiscal year, it expects $0.18 EPS on $802.67M revenue, with a 50% EPS growth. NEO has a Zacks Rank of #2 (Buy) and a VGM Score of B. Halozyme Therapeutics (HALO) is also highlighted as a strong performer in the industry.

Original reporting

finance.yahoo.com

Published Aug 24, 2026, 1:15 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Aug 24, 2026, 2:20 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

NeoGenomics, Inc. (NEO) Hits Fresh High: Is There Still Room to Run? — source image — Source · finance.yahoo.com

Decision brief

The 30-second read

$NEOBullishMed

Why it matters

The earnings beat reinforces the bullish narrative, but valuation metrics warn of overextension.

Market read

Earnings beat and guidance may drive short‑term price appreciation, while high multiples could temper longer‑term gains.

What to watch

High PEG and premium valuation could limit upside if growth slows.

Relevance 8/10Novelty 8/10Timing: post‑earnings release today

Background

NeoGenomics has a track record of earnings surprises and a Zacks Rank #2 (Buy).

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$NEOBullishHigh confidence

Context

NeoGenomics reported EPS $0.05 vs $0.03 estimate and provided FY guidance of $0.18 EPS on $802.67M revenue.

Expected impact

Potential short‑term rally, target +10% over next 2‑3 weeks.

Evidence & confidence

Beat of consensus and strong forward‑looking earnings growth indicate positive earnings momentum.

Market effects

Sector

Highlights strength in the Medical – Biomedical and Genetics sector, may lift peers.

Regional

Positive for US biotech stocks, modest effect on broader market.

Global

Limited to biotech investors; no global macro impact.

Counterpoint

What could challenge this read

Valuation appears stretched (94.3x FY EPS) suggesting potential pullback risk.

Key entities

company
NeoGenomics, Inc.
US‑listed molecular diagnostics firm.

Read at source ← All news

SEP 16

$RDNTHighAI 8/10

Testing & Diagnostics Services Stocks Q2 Results: Benchmarking Guardant Health (NASDAQ:GH)

Guardant Health, RadNet (NASDAQ:RDNT), Labcorp (NYSE:LH), NeoGenomics (NASDAQ:NEO), and Quest (NYSE:DGX) reported Q2 results. RadNet saw 25% revenue growth, beating estimates. Labcorp's revenue grew 5.8%, meeting expectations but underperforming peers. NeoGenomics and Quest both beat estimates with 11.2% and 10.2% revenue growth, respectively. Stocks have risen since reporting.

yahoo.com3 min

AUG 28

$NEOHighAI 8/10

Biotech Stocks At 52-Week Highs - NEO, BLSM, RVMD, ORMP, CADL

NeoGenomics (NEO), BlossomHill Therapeutics (BLSM), Revolution Medicines (RVMD), Oramed Pharmaceuticals (ORMP), and Candel Therapeutics (CADL) reached 52-week highs on August 27, 2026. NEO reported Q2 revenue growth of 11% and a profit turnaround. BLSM began trading on Nasdaq and received FDA Fast Track designation. RVMD's lead drug, Rasonque, was FDA-approved. ORMP's net income increased significantly. CADL reported a higher net loss but plans a BLA filing for its lead drug.

rttnews.com4 min

AUG 27

Med

Medicare Expands Coverage for NeoGenomics RaDaR ST Assay for Immunotherapy

NeoGenomics' RaDaR ST assay received expanded Medicare coverage for immunotherapy monitoring in late-stage solid tumors, adding to its existing indications. The assay helps track treatment response and distinguish true progress from inflammation. According to the company, it detects circulating tumor DNA at low levels, supporting recurrence risk assessment and treatment monitoring.

clpmag.com2 min

JUL 30

$NEOHighAI 9/10

NeoGenomics Q2 Earnings Call Highlights

NeoGenomics (NASDAQ: NEO) reported Q2 adjusted gross margin of 48.1% and adjusted EBITDA of $14.4 million. It raised 2026 revenue guidance to $802 million to $806 million and adjusted EBITDA to $56 million to $58 million. Management discussed RaDaR ST and PanTracer LBx reimbursement progress, NovaSeq X transitions, and a $316 million convertible note raise. Cash was $145.5 million.

yahoo.com7 min

JUL 30

$SPRCHighAI 8/10

Top Biotech Gainers: SPRC On Watch, AVTR, NEO Boost Full-Year Outlook, SMTI Scooped Up

Biotech gainers included SciSparc (SPRC) after its subsidiary NeuroThera Labs completed internal validation of a quantum sampling platform. Avantor (AVTR) rose after Q2 results and raised 2026 adjusted EPS to $0.80-$0.83. NeoGenomics (NEO) lifted 2026 revenue guidance to $802-$806M. Other movers: Alvotech (ALVO) on FDA facility inspection, Sanara MedTech (SMTI) to be acquired by MiMedx (MDXG), and LB Pharmaceuticals (LBRX) after a ~$150M private placement.

rttnews.com3 min

JUL 29

$NEOMedAI 9/10

Why NeoGenomics (NEO) Stock Is Up Today

NeoGenomics (NEO) shares rose 15.8% after the company reported Q2 2026 adjusted EPS of $0.05 on revenue of $201.7 million, beating Wall Street forecasts of $0.03 and $197.3 million. NeoGenomics also raised full-year guidance to about $804 million revenue and $0.19 adjusted EPS.

financialcontent.com4 min